MetaCap

Aurinia Pharmaceuticals (AUPH) vs Trevi Therapeutics (TRVI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Trevi Therapeutics (TRVI) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 21.5% versus a loss of 6.3%. Over five years, TRVI leads with a +1235.0% price change compared with -24.0% for AUPH. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.90 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUPH-6.25%TRVI+21.47%
+82%+33%-15%
Nov 21, 20251 yearNov 20, 2026
AUPH-48.37%TRVI+1159.43%
+1788%+807%-174%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUPH versus TRVI key metrics
MetricAUPHTRVI
Share price$14.70$13.35
Market cap$1.97B$1.90B
1-day change-1.28%-2.70%
YTD return-7.84%+6.63%
1-year return-6.25%+21.47%
5-year return-23.95%+1235.00%
P/E ratio (TTM)6.45—
Forward P/E12.67—
EPS (TTM)$2.28$-0.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$283.06M—
Revenue growth (YoY)+20.38%—
Net income (latest FY)$287.20M$-42.76M
Gross margin88.46%—
Operating margin37.06%—
Net margin101.47%—
52-week high$19.25$20.22
52-week low$13.52$9.82
Distance from 52-week high-23.64%-33.98%
Analyst consensusbuystrong_buy
Avg. price target upside+25.85%+111.09%
Average volume858.74K2.00M
Shares outstanding134.00M142.56M
Employees12834
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TRVI has outperformed AUPH by 27.7 percentage points over the past year.

About Aurinia Pharmaceuticals

AUPH stock →

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Trevi Therapeutics

TRVI stock →

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

AUPH vs TRVI FAQ

Which is bigger, Aurinia Pharmaceuticals or Trevi Therapeutics?

Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.90B for Trevi Therapeutics (TRVI).

Which stock has performed better over the past year, AUPH or TRVI?

TRVI returned +21.47% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.

Are Aurinia Pharmaceuticals and Trevi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons